SYRE
HealthcareSpyre Therapeutics, Inc. · Biotechnology · $4B
What is Spyre Therapeutics, Inc.?
Spyre Therapeutics is a preclinical-stage biotechnology company focused entirely on developing treatments for inflammatory bowel disease. Headquartered in Waltham, Massachusetts, the company is building a pipeline of monoclonal antibody therapies targeting IBD subtypes including ulcerative colitis and Crohn's disease.
Spyre Therapeutics designs and advances monoclonal antibody candidates aimed at specific biological targets implicated in inflammatory bowel disease. Its approach centers on both single-mechanism antibodies and combination therapies that pair multiple mechanisms of action. The company generates no product revenue at this stage — it operates as a research and development organization, funding its pipeline through capital markets while working to advance candidates toward clinical trials.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- SPY001 — anti-α4β7 integrin monoclonal antibody for IBD
- SPY002 — anti-TL1A monoclonal antibody candidate
- SPY120 — combination of SPY001 and SPY002 antibodies
- SPY003 — anti-IL-23 monoclonal antibody program
- SPY130 / SPY230 — additional dual-mechanism combination candidates
Is SYRE a Good Stock to Buy?
UQS Score rates SYRE as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of preclinical biotechs.
The most constructive element in SYRE's UQS profile is its Risk pillar, which scores Good — suggesting the company's balance sheet and near-term financial stability are relatively manageable compared to peers at a similar stage of development.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products, no revenue, and an unproven pipeline. Valuation is rated Elevated, meaning the market is pricing in significant future success that has yet to be demonstrated.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SYRE pay dividends?
No — Spyre Therapeutics, Inc. does not currently pay a dividend.
Spyre Therapeutics does not pay a dividend. As a preclinical-stage biotech, the company directs all available capital toward research, pipeline advancement, and operations. Investors in SYRE are taking a pure growth and development bet — income-oriented investors should look elsewhere.
When does SYRE report earnings?
Spyre Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a preclinical company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline milestones rather than revenue or profitability. Progress updates on clinical readiness and capital position tend to drive market reaction more than traditional earnings metrics.
For the most recent quarter's results and pipeline updates, visit Spyre Therapeutics' investor relations page directly.
SYRE Price History
-56.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Spyre Therapeutics, Inc.?
Based on Spyre Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SYRE Long-term Outlook
With Growth and Quality both rated Weak, SYRE's near-term fundamental outlook is shaped almost entirely by binary pipeline events rather than financial momentum. The Good Risk rating provides some reassurance around capital adequacy, but the Elevated Valuation label suggests the stock already reflects optimistic assumptions about pipeline success. The path to improving its UQS profile runs through clinical data readouts and eventual regulatory progress.
Growth drivers
- Advancement of SPY001 and SPY002 into clinical-stage trials
- Potential validation of combination therapy approach in IBD
- Growing unmet need in ulcerative colitis and Crohn's disease treatment
Key risks
- Preclinical pipeline carries high probability of clinical failure
- Elevated valuation leaves little margin for setbacks
- Continued cash consumption with no near-term revenue visibility
SYRE vs Peers
Spyre Therapeutics operates in a competitive specialty biotech landscape alongside other companies developing treatments for rare and inflammatory diseases.
Crinetics focuses on rare endocrine diseases and has candidates in more advanced clinical stages than Spyre's current preclinical programs.
Amicus targets rare metabolic and genetic diseases, with an approved commercial product giving it a revenue base that Spyre currently lacks.
Ligand operates a royalty-based business model across a broad portfolio of partnered drugs, offering a very different risk and revenue profile compared to Spyre's single-focus pipeline.
Frequently Asked Questions
What does Spyre Therapeutics do?
Spyre Therapeutics is a preclinical-stage biotech developing monoclonal antibody therapies for inflammatory bowel disease. Its pipeline targets IBD subtypes including ulcerative colitis and Crohn's disease through both single-mechanism and combination antibody approaches. The company has no approved products and is focused on advancing its candidates toward clinical trials.
Does SYRE pay dividends?
No, Spyre Therapeutics does not pay a dividend. The company is in the preclinical stage with no product revenue, so all capital is directed toward research and pipeline development. Dividend income is not part of the SYRE investment thesis at this stage.
When does SYRE report earnings?
Spyre Therapeutics follows a standard quarterly reporting cadence for US-listed companies. Because it is preclinical, reports center on operating expenses and cash runway rather than revenue. Check the company's investor relations page for the most current schedule and results.
Is SYRE a good stock to buy?
UQS Score rates SYRE as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars. The Risk pillar is Good, but Valuation is Elevated. This profile is typical of early-stage biotechs where outcomes depend heavily on clinical and regulatory events rather than current financial performance.
Is SYRE overvalued?
UQS Score's Valuation pillar for SYRE is rated Elevated, suggesting the current market price reflects optimistic expectations about pipeline success that have not yet been validated by clinical data. Investors should weigh this against the binary nature of preclinical drug development.
How does SYRE compare to its competitors?
Compared to peers like Amicus Therapeutics and Ligand Pharmaceuticals, Spyre is at an earlier stage with no commercial products or royalty income. Crinetics is also development-stage but has candidates further along clinically. Spyre's differentiation lies in its IBD-specific combination antibody strategy, which is relatively novel in the space.
What is SYRE's market cap bracket?
Spyre Therapeutics is classified as a mid-cap company. This is notable for a preclinical biotech, reflecting market expectations around the potential of its IBD pipeline rather than current revenues or earnings.
Who founded Spyre Therapeutics?
The company was originally incorporated in 2013 as Aeglea BioTherapeutics and rebranded as Spyre Therapeutics in November 2023 following a strategic pivot toward IBD. Founding and leadership details are publicly available through the company's SEC filings and investor relations materials.
Is SYRE a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates SYRE as Poor. Weak Quality, Moat, and Growth pillars reflect the realities of a company with no revenue and an unproven pipeline. Long-term quality potential exists only if clinical programs advance successfully — a high-risk proposition at this stage.
What is the main competitive advantage of Spyre Therapeutics?
Spyre's differentiation lies in its combination antibody strategy — pairing multiple mechanisms of action in a single therapy for IBD. If validated clinically, this approach could offer advantages over existing single-target treatments. However, the Moat pillar is currently rated Weak, as no commercial product or proven advantage has been established yet.
What sector does SYRE belong to?
Spyre Therapeutics operates in the Healthcare sector, specifically within biotechnology. It is focused on a single therapeutic area — inflammatory bowel disease — making it a concentrated, disease-specific biotech rather than a diversified healthcare company.
Unlock Full SYRE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare SYRE against sector peers side by side
- ✓See full risk and valuation breakdown for SYRE
- ✓Track UQS Score changes as new data arrives
Pro Analysis
SYRE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 16.6 | 0.0 | 9.0 | 18.5 | 70.8 | 0.0 | -0.9 |
| Apr 2, 2026 | 17.5 | 0.0 | 9.0 | 23.1 | 70.8 | 0.0 | — |
SYRE — Pillar Breakdown
Quality
— 0.0/100 (25%)Spyre Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Spyre Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 70.8/100 (15%)Spyre Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Spyre Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Spyre Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SYRE.
Score Composition
Financial Data
More Stock Analysis
How is the SYRE UQS Score Calculated?
The UQS (Unified Quality Score) for Spyre Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Spyre Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Spyre Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.